Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 3/20 | 0.48 |
| ▸ | SCN1A | P35498 | 2/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8684485 | 1.00 | LMNA (0.58) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL10639362 | 1.00 | LMNA (0.58) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL1446334 | 0.83 | LMNA (0.61) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL8910044 | 0.82 | NPSR1 (0.47) | LMNACYP1A2AGTR1KDM4ESCN4A | |
| SCHEMBL8138742 | 0.81 | LMNA (0.54) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL18295381 | 0.80 | SCN4A (0.66) | LMNACYP1A2SMN1; SMN2KDM4ESCN4A | |
| SCHEMBL29120476 | 0.80 | LMNA (0.58) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL1496733 | 0.80 | LMNA (0.68) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL8607298 | 0.80 | SCN4A (0.66) | LMNACYP1A2SMN1; SMN2KDM4ESCN4A | |
| SCHEMBL29641315 | 0.80 | SCN4A (0.66) | LMNACYP1A2SMN1; SMN2KDM4ESCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492325-B2 | Compounds as inhibitors of sodium channels | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2022-11-08 | — | — | US | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
| US-5811424-A | CONTROL OF DOWNY MILDEW, LATE BLIGHT | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0113910-B1 | ISOCARBOSTYRIL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |
| EP-0165110-B1 | OPTICALLY ACTIVE ISOCARBOSTYRIL DERIVATIVES AND A METHOD OF PREPARING THE SAME | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1988-12-28 | — | — | EP | disclosed |
| US-4769472-A | Intermediate thieno-isoxazoles and -pyrazoles and 5-benzoyl-4-bromothiophenes | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-09-06 | — | — | US | disclosed |
| US-4728651-A | SYSTEMIC OR OCULAR | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-03-01 | — | — | US | disclosed |
| US-4659833-A | FOUR OPTICAL ISOMERS OF 1-(2'-(O-METHOXYPHENYL)-1'-METHYLETHYLAMINO)-3-(4\"-ISOCARBOSTYRILOXY)-2 -PROPANOL ISOLATED BY LIQUID CHROMATOGRAPHY | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1987-04-21 | — | — | US | disclosed |
| EP-0165110-A1 | Optically active isocarbostyril derivatives and a method of preparing the same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1985-12-18 | — | — | EP | disclosed |
| US-4526893-A | Pharmaceuticals | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1985-07-02 | — | — | US | disclosed |
| US-4503067-A | HYPOTENSIVE, ANGINA PECTORIS | BOEHRINGER MANNHEIM GMBH (DE) | 1985-03-05 | — | — | US | disclosed |
| EP-0113910-A1 | Isocarbostyril derivatives, processes for their preparation and pharmaceutical compositions containing them | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1984-07-25 | — | — | EP | disclosed |
| EP-0004920-B1 | DERIVATIVES OF CARBAZOLYL-4-OXYPROPANOLAMINE, METHODS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1981-08-05 | — | — | EP | disclosed |
| EP-0004920-A1 | Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them | Roche Diagnostics GmbH (DE) | 1979-10-31 | — | — | EP | disclosed |
| US-4083997-A | ANTIDEPRESSANTS | SANDOZ, INC. (US) | 1978-04-11 | — | — | US | disclosed |
| US-3994961-A | ANTIDEPRESSANTS | SANDOZ, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | SCN1B, CACNA1E, SCN2B | LMNA 1789/4885CYP1A2 3286/4885AGTR1 92/4885 |
| US-11492325-B2 | Compounds as inhibitors of sodium channels | SCN1B, CACNA1E, SCN2B | LMNA 1789/4885CYP1A2 3286/4885AGTR1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.